Ratings by UBS (Alan Gould)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/2/2025 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/11/2025 | Incyte | INCY | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/31/2019 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2019 | Celgene | CELG | Downgrade | Neutral (Buy) |
87.45 (108.24) |
23.77% | Details | |
| 1/16/2019 | Incyte | INCY | Downgrade | Neutral (Buy) |
73.54 (128.58) |
74.84% | Details | |
| 11/7/2018 | Spark Therapeutics | ONCE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/31/2018 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/26/2018 | Celgene | CELG | Maintain | Buy (N/A) |
|
Details |
